Skip to main content
Download PDF

Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes

BMC Veterinary Research volume 16, Article number: 125 (2020) Cite this article

Abstract

Background

The microenvironment within solid malignant tumors, including feline mammary gland carcinomas (FMGCs), is commonly hypoxic, possibly due to the lack of functional blood vessels in rapidly proliferating neoplastic tissue. Malignant cells can undergo genetic and adaptive changes that prevent them from dying due to oxygen deprivation through expressions of hypoxia-inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF). Therefore, HIF-1α and VEGF are ideal biomarkers for cancer therapy and prognostic evaluation. The aims of this study were to evaluate the expression of HIF-1α and VEGF in feline mammary carcinomas and analyze their correlations with clinical and pathological factors, such as clinical stage, histologic grading, regional metastasis, and overall survival rate.

Results

Paraffin-embedded tissue samples collected from 72 cats with FMGCs were retrospectively studied. Histologic pattern and histologic grading (Elston and Ellis grading system) of these FMGCs were determined. Our data indicated that grade II tubulopapillary carcinomas (43/72, 59.7%) prevailed in this study, and most FMCGs showed apparent necrosis, squamous metaplasia, and intratumoral stromal response. According to the results of immunohistochemical (IHC) stainings performed in tissue microarrays (TMAs), HIF-1α and VEGF overexpressions were respectively noted in 69.4% (50/72) and 77.8% (56/72) of FMGC cases. Chi-square test showed no correlation of HIF-1α overexpression with clinical and pathological factors. VEGF overexpression was significantly correlated with histologic pattern (p = 0.021), stromal response (p = 0.048), squamous metaplasia (p = 0.001), and lymphovascular invasion (p = 0.007). However, neither HIF-1α nor VEGF overexpression was correlated with histologic grading and metastasis. Of 38 cats with 1-year follow-up, IHC stainings of HIF-1α and VEGF were performed on whole tissue sections. The results showed that overexpression of HIF-1α was significantly correlated with the overall survival rate (p < 0.05) (log-rank test), whereas there was no significant correlation between VEGF overexpression and overall survival rate.

Conclusions

This study suggests that the overexpression of HIF-1α may indicate poor prognosis/overall survival rate in cats with FMGCs. Developing compounds that inhibit HIF-1α may be a potential approach to FMGC treatment.

Background

Mammary neoplasia is the third most common neoplasia affecting female cats [1]. Feline mammary gland carcinomas are frequently reported with local recurrence and distant metastasis, resulting a high mortality rate [2]. Based on clinical and pathological similarities between FMGCs and human breast cancers, FMGCs have been considered an excellent animal model for the human counterpart [3, 4]. Several clinical and pathological parameters are prognostic for both human breast cancers and FMGCs [5]. Immunohistochemical (IHC) staining is emerging as a method for understanding the molecular pathogenesis of FMGCs, and such understanding may further contribute to FMGC therapies and comparable research on human breast cancers.

A hypoxic microenvironment is frequently present in many solid malignant tumors, including FMGCs. It may be due to the lack of functional blood vessels in rapidly proliferating neoplastic tissue [6]. A prolonged and severely hypoxic condition is usually fatal for neoplastic cells, and thus they will undergo genetic and adaptive changes to accommodate the hypoxic condition [7, 8]. Furthermore, several previous studies have demonstrated that an insufficient level of cellular oxygen is significantly correlated with carcinogenesis, cancerous invasion/metastasis and cell death [8,9,10].

Hypoxia-inducible factor 1-alpha (HIF-1α) plays a crucial role in neoplastic cells responding to low-oxygen tension in a variety of physiologic processes, including angiogenesis, tumorigenesis and metastasis [11, 12]. After neoplastic cells are exposed to hypoxia, the amount of HIF-1α heterodimerization with the HIF-1β protein (ARNT) rapidly increases, leading to increases in the HIF-1 protein in the nucleus/cytoplasm [13, 14]. The amount of HIF-1α protein in the nucleus indicates the functional activity of the HIF-1 complex, which may alter the genetic transcription involving angiogenesis, including vascular endothelial growth factor (VEGF) [14]. VEGF overexpression is correlated with the degree of tumor vascularization, tumor progression and diagnosis in many human breast cancers [15]. Furthermore, HIF-1α and VEGF are novel biomarkers for cancer therapy and have led to a great shift in drug development.

In veterinary pathology, although VEGF has been documented as a good prognostic marker for FMGCs, some previous studies have demonstrated inconsistent findings [16,17,18,19]. Furthermore, no studies on the overexpression of HIF-1α in FMGCs have been reported. Therefore, the aims of the present study were (1) to construct FMGC tissue microarrays (TMAs) from the archives for the period of January 2015 to December 2015 at the Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, (2) to immunohistochemically investigate the overexpression of HIF-1α and VEGF in FMGCs, and (3) to evaluate whether the overexpression of VEGF and/or HIF-1α is significantly correlated with clinical and pathological factors, such as clinical stage, histologic grading, regional metastasis, and overall survival rate.

Results

Clinical and pathological information on the cases of FMGCs

Of the 72 feline mammary carcinoma tissues obtained, 45 cases were from spayed females and 3 were from males (1 intact and 2 castrated). The median age was 11.6 ± 3.04 (4–19). No patients had history of chemotherapy or radiotherapy during the survey. On the basis of histologic pattern, tubulopapillary carcinoma was the most common pattern of FMGCs (52/72, 72.2%), followed by solid carcinoma (10/72, 13.9%), cribriform (6/72, 8.3%), and micropapillary invasive carcinoma (4/72, 5.6%). Lymphovascular invasion was found in 48.6% (35/72) of the cases. The results of histologic grading demonstrated that grade II FMGCs (59.7%, 43/72) prevailed in this study. Sixteen of the 26 submitted lymph nodes had metastasis. In addition, most cases had obvious necrosis, squamous differentiation, and intratumoral stromal response.

Overexpression and pattern of HIF-1α and VEGF in FMGCs

HIF-1α overexpression was detected in 69.4% (50/72) of the FMGC cases by using constructed TMAs. The positive signals of HIF-1α in neoplastic cells were mainly nuclear, but mixed nuclear/cytoplasmic positivity was occasionally noted. Neoplastic cells with HIF-1α overexpression were scattered throughout the neoplasm and frequently observed nearby the necrosis (Fig. 1a, b). VEGF overexpression was observed in 77.8% (56/72) of the FMGC cases. Cytoplasmic VEGF positive signals were noted in neoplastic cells and occasionally observed in stromal cells (Fig. 1c, d). IHC stainings of HIF-1α and VEGF from 38 FMGC cases with 1-year follow-up were performed on whole tissue sections, and overexpressions of HIF-1α and VEGF were noted respectively in 78.9% (30/38) and 89.5% (34/38) of the FMGC cases.

Fig. 1
figure1

HIF-1 α and VEGF immunohistochemical expression in feline mammary gland carcinomas (FMGCs). a. Perinecrotic pattern of HIF-1 α expression, b. Diffuse pattern of HIF-1α expression, c. Cytoplasmic VEGF expression, d. Cytoplasmic VEGF expression in neoplastic epithelial cells and mesenchymal stromal cells of FMGCs. Magnification, × 40 (panels a-d)

Full size image

Correlations between HIF-1α/VEGF overexpression and clinical/pathological factors

The correlations between HIF-1α/VEGF overexpression and clinical/pathologic characteristics are summarized in Table 1. There were no significant correlations between HIF-1α expression and clinical/pathological factors. VEGF overexpression was significantly correlated with histologic pattern (p = 0.021, Chi-square), stromal response (p = 0.048, Chi-square), squamous differentiation (p = 0.001, Chi-square), and lymphovascular invasion (p = 0.007, Chi-square). VEGF overexpression was observed in all solid carcinomas (n = 10). VEGF overexpression was not correlated with other clinical and pathological parameters, including age, reproductive status, clinical stage, tubule formation, mitotic count, necrosis, lymph node metastasis, and histologic grading. Spearman analysis indicated that the HIF-1α overexpression was not statistically correlated with VEGF overexpression (p = 0.057, r = 0.226) in FMGCs.

Table 1 Association between HIF-1α or VEGF and clinical/pathological factors by using TMAs
Full size table

Correlation between pathological factors and overall survival rate

Thirty-eight of the 72 cases had 1-year follow-up. Twelve patients were still alive and 26 were dead. Therefore, the 1-year overall survival rate for all patients was 31.6% (12/38). In this study, the Elston and Ellis (EE) and Revised Elston and Ellis (REE) grading systems had prognostic significance for FMGCs (p = 0.001, log-rank test, Fig. 2c). Necrosis (p = 0.035, log-rank test), stromal response (p = 0.030, log-rank test) and squamous metaplasia (p = 0.015, log-rank test) were significantly associated with prognosis. However, there was no significant correlation between lymphovascular invasion and overall survival rate (p > 0.05, log-rank test, Fig. 2d).

Fig. 2
figure2

Kaplan-Meier curves of overall survival rate for 38 cats with mammary gland carcinoma using whole tissue sections. a. Cats with HIF-1 α overexpression had a significantly lower overall survival rate compared with those with HIF-1 α without overexpression. b. VEGF overexpression was not correlated with the overall survival rate of cats with FMGCs. c. Elston and Ellis grading system was significantly correlated with overall survival rate. d. No significant correlation between lymphovascular invasion and lower overall survival rate

Full size image

Correlation between HIF-1α/VEGF overexpressions and overall survival rate

HIF-1α and VEGF overexpressions were demonstrated in 65.8% (25/38) and 76.3% (29/38) of the FMGCs by using TMAs. Furthermore, the IHC stainings of HIF-1α and VEGF on whole tissue sections indicated HIF-1α and VEGF overexpressions in 78.9% (30/38) and 89.5% (34/38) of the FMGCs, respectively.

There was a significant correlation between HIF-1α overexpression and overall survival rate. When whole tissue sections were used, the 1-year overall survival rates for FMGC cases with and without HIF-1α overexpression were respectively 80% (24/30) and 25% (2/8) (p = 0.033, log-rank test, Fig. 2c), but no significant correlation between HIF-1α overexpression and OS rate was found with TMAs (p = 0.086, log-rank test). The 1-year overall survival rates for FMGC cases with and without VEGF overexpression were 70.0% (24/34) and 40.0% (2/4) in the whole sections. No significant correlation between VEGF overexpression and overall survival rate was found either by TMAs (p = 0.617, log-rank test) or whole tissue sections (p = 0.285, log-rank test, Fig. 2d).

Discussion

Several studies have demonstrated that tumor hypoxia through activation of angiogenesis assists in tumor progression and metastasis, which also makes solid tumors resistant to radiation and chemotherapy [20]. HIF-1α is a marker of hypoxia, which activates gene encoding glucose transporters, glycolytic enzymes, and VEGF [14]. It is widely accepted and confirmed in humans that HIF-1α causes the angiogenic switch via VEGF [14]. This retrospective study evaluated the overexpressions of HIF-1α and VEGF in FMGCs and investigated the correlations among the overexpressions of HIF-1α/VEGF, clinical/pathological factors, and clinical outcomes.

HIF-1α has been found to be overexpressed in a variety of human cancers, such as colon, breast, gastric, lung, skin, ovarian, pancreatic, prostate, and renal carcinomas [21,22,23]. In humans, the amount of HIF-1α is higher in primary and metastatic neoplasms than in the respective non-neoplastic tissues. To the best of our knowledge, this is the first IHC study of HIF-1α in FMGCs. Our study demonstrated that 69.4% (50/72) of the FMGCs had HIF-1α overexpression. VEGF has been studied in many human neoplasms, such as lung, breast, gastrointestinal tract, renal, and ovarian carcinomas [24,25,26,27,28]. A humanized anti-VEGF monoclonal antibody (bevacizumab; Avastin) has been approved as a first-line treatment for metastatic colorectal cancer in humans [29]. In our case, VEGF was positive in 77.8% (56/72) of the FMGCs. As noted above, HIF-1α and VEGF overexpressions in FMGCs are not uncommon.

The positive signals of HIF-1α were diffusely distributed throughout the FMGC or restricted to perinecrotic neoplastic cells, consistent with the pattern of HIF-1α in human breast cancers [30]. In addition, our results of univariate analysis (Kaplan-Meier) demonstrated that HIF-1α overexpression was significantly correlated with a lower overall survival rate and considered a potential prognostic factor in FMGCs. This finding is consistent with previous studies of human breast cancers [31,32,33,34,35]. In this study, we used a threshold (> 0% positive nuclei/5 representative high power fields) for HIF-1α that was different from the thresholds (> 1%, or > 10% positive nuclei/5 representative high power fields) used in previous studies conducted in humans [30, 31, 36,37,38,39]. Furthermore, there is no significant association between overall survival rate and HIF-1α overexpression in FMGCs if the thresholds for HIF-1α (> 1%, or > 10% positive nuclei/5 representative high power fields) are used. According to this finding, > 0% is considered an optimal prognostic threshold for FMGCs. VEGF overexpression was not found to be significantly correlated with overall survival rate in this study, which is consistent with some of the previous studies of FMGCs [16,17,18,19]. A previous study has demonstrated that VEGF overexpression is significantly correlated with clinical outcome [16]. However; the prognostic threshold for VEGF is 72.1%, which is not a conventional method to evaluate the result of VEGF expression [16]. Therefore, a more conventional scoring principle to evaluate VEGF expression, one used in recent studies in FMGCs and human breast cancers, was chosen in this study [19, 40].

The correlation between HIF-1α and VEGF overexpressions was not significant in the present study. Previous studies have suggested that HIF-1α overexpression can occur in an early stage of breast cancer (before the presence of angiogenesis or invasion) [8, 36]. Therefore, it is speculated that the regulation of HIF-1α and VEGF expressions in FMGCs may be more complicated than or different from that in humans. Although the expression of VEGF is up-regulated during hypoxia by HIF-1α, the significant correlation between their IHC stainings is still controversial in previous human studies of gastric cancer, non-small cell lung cancer, and esophageal carcinoma [41,42,43]. They have pointed out that factors other than HIF-1α can regulate VEGF expression [41,42,43]. Many factors such as hormones, cytokines and cellular stress can regulate VEGF transcription as well [44].

The advantages of using TMAs include cost-effectiveness and rapid simultaneous molecular profiling of tissue samples from large cohorts. However, few studies have used TMAs in feline tissue [45, 46]. The weakness of TMAs is the relatively small size of samples, and thus the representativeness may vary among different samples. TMAs can be a useful method to detect VEGF expression in FMGCs because it tends to be large-scale. However, the use of TMAs for evaluating the HIF-1α expression in FMGCs may be limited due to the low expression level and the restrictive tissue distribution (such as perinecrotic tissue) of HIF-1α. Most importantly, TMAs are usually constructed by taking the most representative areas without marked necrosis or inflammation to reserve more neoplastic cells, and it may conflict with the expression pattern of HIF-1α, which is usually perinecrotic distribution. Therefore, the whole tissue sections of 38 cats with 1-year follow-up were used for investigating the correlation between HIF-1α overexpression and overall survival rate.

Several prognostic indexes for FMGCs have been advanced in previous studies, including clinical stage, tumor grading, and proliferation markers [5, 47]. In general, veterinary pathologists follow the World Health Organization morphological classification of feline mammary tumor to categorize the histologic types of FMGCs, but no significant correlation between histologic type and prognosis has been indicated, except the invasive micropapillary carcinoma [48, 49]. A previous study has demonstrated that invasive micropapillary carcinomas have a distinct histologic pattern with more aggressive biological behavior and poor clinical outcome [49]. Although this statement cannot be supported in this study due to the small sample size (n < 5), the cats with invasive micropapillary carcinomas were all dead within 1 year, and thus the 1-year overall survival rate was 0%.

The EE grading system is a gold standard for the histologic grading of human breast cancers, but it may be of limited utility in FMGCs [50]. The Revised EE (REE) and the novel grading system for FMGC have been advanced for their prognostic value of histologic grading [50]. Although the REE grading system is prognostic for FMGCs, no significant correlation between the novel grading system and overall survival rate was indicated in our study. Therefore, it is presumed that the correlation between pathological factors and prognosis may be different in different countries and feline breeds. Therefore, to determine or predict the prognosis of cats with FMGCs, all clinical/pathological parameters should be of concern.

In conclusion, this study suggests that the overexpression of HIF-1α indicates poor prognosis in cats with FMGCs. HIF-1α might therefore be a useful biomarker for feline cancer therapy and prediction of the clinical outcome, and thus developing compounds that inhibit HIF-1α may be a potential approach to FMGCs treatment. In addition, there are some limitations in this study. Two major concerns are 1) the sample size in this study is relatively small. 2) the nature of this study is retrospective and our results are still preliminary. Thus, further investigations on the mRNA expression levels of HIF-1α and VEGF by RNAscope® technology and other molecules involved in their upstream and downstream of the signaling pathway based on an bigger sample size are warranted to determine the potential molecular pathogenesis of FMGCs.

Conclusions

This is the first study that investigates the expression and the prognostic significance of HIF-1α in feline mammary carcinomas. The results showed that overexpression of HIF-1α was significantly correlated with the overall survival rate, whereas there was no significant correlation between VEGF overexpression and overall survival rate. Given the major role of HIF-1α in compensating for oxygen deficiency by increasing availability of oxygen or providing metabolic adaptation of tumor cells, the inhibition of this activity might provide a potential approach to FMGC treatments.

Methods

The FMGCs used in this study were obtained from the archives of the Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University. The samples were surgically obtained by mastectomy or block dissection from cats of different breeds (n = 72). Formalin-fixed and paraffin wax-embedded tissue blocks were prepared and available as hematoxylin and eosin (HE)-stained sections. Clinical data including age, reproductive status, and clinical stage were obtained [51]. All of the FMGC cases included in the study were followed up for at least 1 year after surgery by the referring veterinary surgeons, and the post-operative courses of FMGCs were evaluated. FMGC cases with follow-up were then grouped into 2 distinct outcomes: (1) alive, and (2) tumor-related death/euthanasia. Other conditions, such as lost to follow-up, non-tumor-related death/euthanasia or death/euthanasia of undetermined causes, were excluded in this study.

Histological examination

Histologic slides were reviewed independently by an assessor, with direct assistance from an experienced veterinary pathologist (Chian-Ren Jeng). FMGCs were classified by different histological patterns, including tubulopapillary, solid, cribriform and micropapillary invasive [49]. In the FMGCs presenting more than one histologic pattern, the most predominant pattern in the tissue sections was chosen.

The histologic grading of FMGCs was determined by using the EE, REE, and novel grading systems [50, 52]. Other information, such as central necrosis, squamous differentiation, stromal response, lymphovascular invasion and the presence of lymph node metastasis, were also documented. Briefly, necrosis and squamous differentiation were classified as 2 separate categories. Necrotic areas of the neoplasm with more than 25% of necrotic areas were classified as “extensive”, while other conditions were regarded as “no to mild”. Stromal response was classified subjectively as follows: (1) none to mild, (2) peritumoral, and (3) intratumoral. Changes consistent with squamous differentiation included at least 2 of the following: decreased N:C ratio, increased cytoplasmic eosinophilia, increased cell size, and increased angularity of cell margin [50]. Squamous differentiation was classified according to proportion of metaplastic cells in all neoplastic cells and divided in 2 subgroups as (1) ≤ 5%, (2) > 5%. A tumor was positive for lymphovascular invasion if neoplastic emboli were clearly seen within an endothelium-lined lymphatic and/or vascular lumens.

Tissue microarray (TMA) construction

TMAs were prepared by Array Biotechnology Co., Ltd. Cylindrical cores of 1.5 mm in diameter were taken from tumor areas of paraffin blocks and inserted into the TMA block. Three tissue arrays were constructed at the same time and composed of the most representative areas without marked necrosis and/or inflammation [45]. Tumor emboli and metastatic tumors in lymph nodes were also included. The TMA blocks were sectioned at 4 μm for subsequent IHC study.

IHC stainings of HIF-1α and VEGF

IHC analysis was performed by using anti-HIF-1α (Clone: H1alpha67; diluted 1:200; Abcam, Cambridge, UK) and VEGF antibody (Clone: A-20; diluted 1:100; Santa Cruz Biotechnology, Inc., CA), which had good cross-reactivity with feline tissues [3, 40]. Tissue sections were deparaffinized in xylene, rehydrated in a graded series of ethanol solutions (100, 100, 95, and 80%), and then microwaved at 95 °C for 45 min for HIF-1α and 30 min for VEGF in commercial trilogy (Cell Marque, California, USA) for antigen retrieval, and then allowed to cool for 20 min. Slides were incubated in 10% nonimmune goat serum (Dako Ltd., Ely, UK) diluted by 1X PBS at room temperature for 30 min. The tissue sections were incubated with anti-HIF-1α and anti-VEGF antibodies respectively for 1.5 h and 1 h at room temperature in a moist chamber. Endogenous peroxidase activity was blocked with a solution of 3% H2O2 in methyl alcohol for 10 min. The slides were incubated with secondary antibody REAL Envision Detection System Peroxidase/DAB+, mouse/rabbit (Dako), for 60 min according to the manufacturer’s instructions. The slides were then stained with 3–3′-diaminobenzide tetrahydrochloride for 3 min. Sections were counterstained with Mayer’s hematoxylin solution. 1 X TBST was used as washing buffer in the procedure of IHC. Negative control included incubation with nonimmune goat serum instead of primary antibody. Feline tissue known to react with HIF-1α and human invasive breast carcinoma known to express VEGF were used as positive controls. IHC stainings of HIF-1α and VEGF were conducted in TMAs of 72 FMGC cases and whole sections of 38 FMGC cases with 1-year follow-up.

Scoring criteria

The positive signals of IHC stainings for both HIF-1α and VEGF were scored by using the previous criteria [19, 40]. HIF-1α was defined as overexpressed when there were any neoplastic cells with nuclear positivity. The presence of cytoplasmic positivity of HIF-1α in neoplastic cells was not indicative. The positive signals of VEGF were mainly observed in the cytoplasm of neoplastic cells, and the score was ascertained by consideration of both staining density and intensity as follows: 0, a complete lack of staining; 1, < 50% positive neoplastic cells with weak staining; 2, weak positive staining in ≥50% of neoplastic cells or strong staining in < 50% of cells; 3, strong positive staining in ≥50% of neoplastic cells. VEGF overexpression is defined as a score of 2 and 3, while VEGF non-overexpression is defined as a score of 0 or 1.

Statistical analyses

Statistical analyses were all performed in Prism (GraphPad Sofware, CA, USA) and IBM SPSS statistics version 22.0 (IBM Corp., Armond, NY). The correlation between HIF-1α/VEGF overexpressions and clinical/pathological factors were performed using chi-square tests. Spearman correlation from ranks was used to analyze the correlation between VEGF and HIF-1α. Curves for 1-year overall survival rate were estimated with Kaplan-Meier analysis, and differences between 2 groups were evaluated using the log-rank test for univariate survival analysis. A p value < 0.05 was considered statistically significant.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request. For more information, please contact the corresponding authors.

Abbreviations

FMGC:

Feline mammary gland carcinoma

HIF-1α:

Hypoxia-inducible factor 1 alph

VEGF:

Vascular endothelial growth factor

TMA:

Tissue Microarray

IHC:

Immunohistochemical

WHO:

World Health Organization.

References

  1. 1.

    MacEwen EG, Hayes AA, Harvey HJ, Patnaik AK, Mooney S, Passe S. Prognostic factors for feline mammary tumors. J Am Vet Med Assoc. 1984;185:201–4.

    CAS  PubMed  Google Scholar 

  2. 2.

    Amorim FV, Souza HJ, Ferreira AM, Fonseca AB. Clinical, cytological and histopathological evaluation of mammary masses in cats from Rio de Janeiro. Brazil J Feline Med Surg. 2006;8:379–88.

    PubMed  Article  Google Scholar 

  3. 3.

    Zappulli V, De Zan G, Cardazzo B, Bargelloni L, Castagnaro M. Feline mammary tumours in comparative oncology. J Dairy Res. 2005;72:98–106.

    CAS  PubMed  Article  Google Scholar 

  4. 4.

    de las Mulas JM, Reymundo C. Animal models of human breast carcinoma: canine and feline neoplasms. Rev Oncología. 2000;2:274–81.

    Google Scholar 

  5. 5.

    Hughes K, Dobson JM. Prognostic histopathological and molecular markers in feline mammary neoplasia. Vet J. 2012;194:19–26.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Dang CV, Semenza GL. Oncogenic alterations of metabolism. Trends Biochem Sci. 1999;24:68–72.

    CAS  PubMed  Article  Google Scholar 

  7. 7.

    Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271–5.

    CAS  PubMed  Article  Google Scholar 

  8. 8.

    Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830–5.

    CAS  PubMed  Google Scholar 

  9. 9.

    Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266–76.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer. 1996;32A:2451–60.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88:1474–80.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KSC, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  13. 13.

    Iyer NV, Kotch LE, Agani F, Leung SW, Laughner E, Wenger RH, et al. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12:149–62.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–13.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  15. 15.

    Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9:311–20.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Millanta F, Lazzeri G, Vannozzi I, Viacava P, Poli A. Correlation of vascular endothelial growth factor expression to overall survival in feline invasive mammary carcinomas. Vet Pathol. 2002;39:690–6.

    CAS  PubMed  Article  Google Scholar 

  17. 17.

    Millanta F, Silvestri G, Vaselli C, Citi S, Pisani G, Lorenzi D, et al. The role of vascular endothelial growth factor and its receptor Flk-1/KDR in promoting tumour angiogenesis in feline and canine mammary carcinomas: a preliminary study of autocrine and paracrine loops. Res Vet Sci. 2006;81:350–7.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Islam MS, Matsumoto M, Hidaka R, Miyoshi N, Yasuda N. Expression of NOS and VEGF in feline mammary tumours and their correlation with angiogenesis. Vet J. 2012;192:338–44.

    CAS  PubMed  Article  Google Scholar 

  19. 19.

    De Campos CB, Damasceno KA, Gamba CO, Ribeiro AM, Machado CJ, Lavalle GE, et al. Evaluation of prognostic factors and survival rates in malignant feline mammary gland neoplasms. J Feline Med Surg. 2016;18:1003–12.

    PubMed  Article  Google Scholar 

  20. 20.

    Brown JM. Tumor hypoxia in cancer therapy. Method Enzymol. 2007;435:297–321.

    CAS  Google Scholar 

  21. 21.

    Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–15.

    CAS  PubMed  Google Scholar 

  22. 22.

    Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Bean JM, Prosnitz LR, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 1996;56:941–3.

    CAS  PubMed  Google Scholar 

  23. 23.

    Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000;20:1527–33.

    CAS  PubMed  Google Scholar 

  24. 24.

    Volm M, Koomagi R, Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer. 1997;74:64–8.

    CAS  PubMed  Article  Google Scholar 

  25. 25.

    Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res. 1996;56:2013–6.

    CAS  PubMed  Google Scholar 

  26. 26.

    Ellis LM, Takahashi Y, Fenoglio CJ, Cleary KR, Bucana CD, Evans DB. Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma. Eur J Cancer. 1998;34:337–40.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  27. 27.

    Tomisawa M, Tokunaga T, Oshika Y, Tsuchida T, Fukushima Y, Sato H, et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer. 1999;35:133–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Sowter HM, Corps AN, Evans AL, Clark DE, Charnock-Jones DS, Smith SK. Expression and localization of the vascular endothelial growth factor family in ovarian epithelial tumors. Lab Investig. 1997;77:607–14.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. 29.

    Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328–35.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005;58:172–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  31. 31.

    Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005;116:734–9.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Saponaro C, Malfettone A, Ranieri G, Danza K, Simone G, Paradiso A, et al. VEGF, HIF-1alpha expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013;8:53070.

    Article  CAS  Google Scholar 

  33. 33.

    Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008;110:465–75.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97:1573–81.

    PubMed  Article  Google Scholar 

  35. 35.

    Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8:1831–7.

    CAS  PubMed  Google Scholar 

  36. 36.

    Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 2005;25:3003–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Pansare V, Munkarah AR, Schimp V, Haitham Arabi M, Saed GM, Morris RT, et al. Increased expression of hypoxia-inducible factor 1alpha in type I and type II endometrial carcinomas. Mod Pathol. 2007;20:35–43.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  38. 38.

    Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1alpha and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. BMC Cancer. 2009;9:432.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  39. 39.

    Saka B, Ekinci O, Dursun A, Akyurek N. Clinicopathologic and prognostic significance of immunohistochemical expression of HIF-1alpha, CXCR4 and CA9 in colorectal carcinoma. Pathol Res Pract. 2017;213:783–92.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Agaoglu OK, Agaoglu AR, Guzeloglu A, Kurar E, Kayis SA, Ozmen O, et al. Expression of hypoxia-inducible factors and vascular endothelial growth factor during pregnancy in the feline uterus. Theriogenology. 2015;84:24–33.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, et al. Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung Cancer. 2005;49:325–35.

    PubMed  Article  Google Scholar 

  42. 42.

    Oh SY, Kwon HC, Kim SH, Jang JS, Kim MC, Kim KH, et al. Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer. 2008;8:123.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  43. 43.

    Takala H, Saarnio J, Wiik H, Ohtonen P, Soini Y. HIF-1alpha and VEGF are associated with disease progression in esophageal carcinoma. J Surg Res. 2011;167:41–8.

    CAS  PubMed  Article  Google Scholar 

  44. 44.

    Pagès G, Pouysségur J. Transcriptional regulation of the vascular endothelial growth factor gene-a concert of activating factors. Cardiovasc Res. 2005;65:564–73.

    PubMed  Article  CAS  Google Scholar 

  45. 45.

    Muscatello LV, Sarli G, Beha G, Asproni P, Millanta F, Poli A, et al. Validation of tissue microarray for molecular profiling of canine and feline mammary tumours. J Comp Pathol. 2015;152:153–60.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Takala H, Kauppila JH, Soini Y, Selander KS, Vuopala KS, Lehenkari PP, et al. Toll-like receptor 9 is a novel biomarker for esophageal squamous cell dysplasia and squamous cell carcinoma progression. J Innate Immun. 2011;3:631–8.

    CAS  PubMed  Article  Google Scholar 

  47. 47.

    Gimenez F, Hecht S, Craig LE, Legendre AM. Early detection, aggressive therapy: optimizing the management of feline mammary masses. J Feline Med Surg. 2010;12:214–24.

    PubMed  Article  Google Scholar 

  48. 48.

    Misdorp W, Else RW, Hellmén E, Lipscomb TP. Histological classification of mammary tumors of the dog and the cat. Washington, DC: Armed Forces Institute of Pathology in cooperation with the American Registry of Pathology; 1999.

    Google Scholar 

  49. 49.

    Seixas F, Palmeira C, Pires MA, Lopes C. Mammary invasive micropapillary carcinoma in cats: clinicopathologic features and nuclear DNA content. Vet Pathol. 2007;44:842–8.

    CAS  PubMed  Article  Google Scholar 

  50. 50.

    Mills SW, Musil KM, Davies JL, Hendrick S, Duncan C, Jackson ML, et al. Prognostic value of histologic grading for feline mammary carcinoma: a retrospective survival analysis. Vet Pathol. 2015;52:238–49.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Sorenmo KU, Worley DR, Goldschmidt MH. Tumors of the mammary gland. In: Withrow SJ, Vail DM, editors. Withrow and Macewan’s small animal clinical oncology. 5th ed. St. Louis: Saunders Elsevier; 2013. p. 538–56.

    Chapter  Google Scholar 

  52. 52.

    Elston CW, Ellis IO, Symmers WC. The breast: Vol. 13 in the systemic pathology series. 3rd ed. London: Churchill Livingstone; 1998.

    Google Scholar 

Download references

Acknowledgements

The authors would like to thank all their colleagues who participated in this study. Partial of this work had been presented by the same research group and published in the Taiwan Veterinary Journal|Vol. 42, No. 04, pp. 219-258 (2016), Proceedings of the Joint Fall Conference and Zoonosis Workshop of the Chinese Society of Veterinary Science and the Taiwan Association of Veterinary Science and Animal Husbandry (CSVS/TAVSAH), 0A-04.

Funding

The author(s) declared that they received no financial support for their research and/or authorship of this article.

Author information

Affiliations

  1. Graduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan

    Bo Chen, Susanne Je-Han Lin, Wen-Ta Li, Hui-Wen Chang, Victor Fei Pang & Chian-Ren Jeng

  2. Institute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan

    Ching-Ho Wu

  3. Department of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan

    Pei-Yi Chu

  4. Department of Pathology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan

    Chin-Cheng Lee

  5. Department of Pathology, The University of Tokyo, Tokyo, Japan

    Hiroyuki Nakayama

Authors
  1. Bo Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susanne Je-Han Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wen-Ta Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hui-Wen Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Victor Fei Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pei-Yi Chu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Chin-Cheng Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroyuki Nakayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ching-Ho Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Chian-Ren Jeng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

BC contributed to the conception and design of the study; contributed to acquisition, analysis, and interpretation of data; drafted the manuscript; and critically revised the manuscript. SJHL, WTL, HWC, VFP and HN contributed to the conception and design of the study, and contributed to the analysis and interpretation of data. PYC and CCL contributed to the acquisition of data. CHW and CRJ contributed to the conception and design of the study; contributed to the acquisition, analysis, and interpretation of data; and critically revised the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Ching-Ho Wu or Chian-Ren Jeng.

Ethics declarations

Ethics approval and consent to participate

This study is a retrospective investigation carried out on archived tissue samples of feline mammary gland tumors. The protocol has been reviewed and approved by the Institute Animal Care and Use Committee (IACUC) of National Taiwan University. The IACUC Approval No. is NTU107-EL-00165. Owners gave written informed consent to the use of clinical data and stored biological samples for teaching and research causes.

Consent for publication

Not applicable.

Competing interests

The authors declare that no competing interests exist.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Chen, B., Lin, S.JH., Li, WT. et al. Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes. BMC Vet Res 16, 125 (2020). https://doi.org/10.1186/s12917-020-02338-y

Download citation

Keywords

  • Feline
  • Mammary gland carcinoma
  • Hypoxia-inducible factor 1 alpha (HIF-1α)
  • Vascular endothelial growth factor (VEGF)

BMC Veterinary Research

ISSN: 1746-6148

Contact us